Puma Biotechnology, Inc. (PBYI) Price Target Analysis
Analyst Rating: Buy
Based on 19 analystsNo Target Data
PBYI trades at Wall Street's consensus target of —.
Current Price$7.56
Average Target—
Low—
Median—
High—
Analyst Target Range
Forward P/E26.1x
(Growth Premium)
PEG Ratio—
Implied Growth-39.5%
(Declining)
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes PBYI achieves its forward estimates and maintains a stable P/E multiple of 26.1x. This scenario reflects the blended consensus of 19 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
PBYI Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Puma Biotechnology, Inc. (PBYI) has a Wall Street consensus price target of N/A, based on estimates from 19 covering analysts. The company has a market capitalization of $385M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, PBYI trades at a trailing P/E of 12.4x and forward P/E of 26.1x. Analysts expect EPS to grow -39.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $6.36, with bear and bull scenarios of $4.01 and $8.38 respectively. Model confidence stands at 43/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+34.3%
Industry Consensus
Avg Forward P/E
31.4x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
 TGTXTG Therapeutics, Inc. | $8.1B | $53.22 | $54.50 | +2.4% | Buy | 38.6x | 13 |
 PTCTPTC Therapeutics, Inc. | $6.6B | $78.98 | $95.83 | +21.3% | Buy | 89.1x | 26 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.62 | $33.67 | +55.7% | Buy | 55.6x | 37 |
 EXELExelixis, Inc. | $13.2B | $51.91 | $47.33 | -8.8% | Buy | 14.7x | 32 |
 NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
 PFEPfizer Inc. | $143.5B | $25.22 | $26.75 | +6.1% | Hold | 8.5x | 39 |
 AZNAstraZeneca PLC | $271.2B | $174.93 | $186.67 | +6.7% | Buy | 17.0x | 41 |
 MCKMcKesson Corporation | $90.2B | $750.63 | $994.86 | +32.5% | Buy | 17.0x | 31 |
 PAHCPhibro Animal Health Corporation | $1.3B | $31.85 | $49.00 | +53.8% | Buy | 10.4x | 14 |
PBYI — Frequently Asked Questions
Quick answers to the most common questions about buying PBYI stock.
What is the PBYI stock price target for 2026?
The consensus price target for PBYI is $N/A, close to the current price of $7.56 (N/A% implied move). Based on 19 analyst estimates, the stock appears fairly valued near current levels.
Is PBYI a buy, sell, or hold?
PBYI has a consensus rating of "Buy" based on 19 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is PBYI stock overvalued or undervalued?
PBYI trades at a forward P/E of 26.069x, representing a moderate valuation. With analysts targeting $N/A (N/A% implied move), the stock appears close to fair value.
How high can PBYI stock go?
The most bullish Wall Street analyst has a price target of $N/A for PBYI, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $8 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover PBYI stock?
PBYI is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 7 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PBYI stock forecast?
The 12-month PBYI stock forecast based on 19 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $6, with bear/bull scenarios of $4/$8.
What is PBYI's fair value based on fundamentals?
Our quantitative valuation model calculates PBYI's fair value at $6 (base case), with a bear case of $4 and bull case of $8. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 43/100.
What is PBYI's forward P/E ratio?
PBYI trades at a forward P/E ratio of 26.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PBYI stock?
PBYI appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PBYI price targets vary so much?
PBYI analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $4-$8 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare